The association of statin therapy with clinicopathologic outcomes and survival among patients with localized renal cell carcinoma undergoing nephrectomy

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 9, 2015, Pages 388.e11-388.e18

  Viers, Boyd R ^a   Houston Thompson, R ^a   Psutka, Sarah P ^a   Lohse, Christine M ^a   Cheville, John C ^a   Leibovich, Bradley C ^a   Tollefson, Matthew K ^a   Boorjian, Stephen A ^a  

^a MAYO CLINIC   (United States)

Author keywords

HGM CoA reductase inhibitor; Localized; Nephrectomy; Renal cell carcinoma; Statin

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; CLINICAL FEATURE; COHORT ANALYSIS; CORRELATION ANALYSIS; DISEASE COURSE; DISTANT METASTASIS; DRUG EFFECT; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEPHRECTOMY; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; CARCINOMA, RENAL CELL; HYPERCHOLESTEROLEMIA; KIDNEY NEOPLASMS; MIDDLE AGED; PATHOLOGY;

AGED; CARCINOMA, RENAL CELL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY;

EID: 84940467414     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2015.01.009     Document Type: Article

References (28)

1. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22. Heart Protection Study Collaborative Group.
2. Chan K.K., Oza A.M., Siu L.L. The statins as anticancer agents. Clin Cancer Res 2003, 9:10-19.
3. Gauthaman K., Fong C.Y., Statins Bongso A. stem cells, and cancer. J Cell Biochem 2009, 106:975-983.
4. Thurnher M., Nussbaumer O., Gruenbacher G. Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin Cancer Res 2012, 18:3524-3531.
5. Gruenbacher G., Thurnher M. Mevalonate metabolism in cancer. Cancer Lett 2015, 356:192-196.
6. Demierre M.F., Higgins P.D., Gruber S.B., Hawk E., Lippman S.M. Statins and cancer prevention. Nat Rev Cancer 2005, 5:930-942.
7. Yu O., Eberg M., Benayoun S., Aprikian A., Batist G., Suissa S., et al. Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol 2014, 32:5-11.
8. Banez L.L., Klink J.C., Jayachandran J., Lark A.L., Gerber L., Hamilton R.J., et al. Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2010, 19:722-728.
9. Nielsen S.F., Nordestgaard B.G., Bojesen S.E. Statin use and reduced cancer-related mortality. N Engl J Med 2012, 367:1792-1802.
10. Wang C., Tao W., Wang Y., Bikow J., Lu B., Keating A., et al. Rosuvastatin, identified from a zebrafish chemical genetic screen for antiangiogenic compounds, suppresses the growth of prostate cancer. Eur Urol 2010, 58:418-426.
11. Cardwell C.R., Hicks B.M., Hughes C., Murray L.J. Statin use after colorectal cancer diagnosis and survival: a population-based cohort study. J Clin Oncol 2014, 32:3177-3183.
12. Cho S.J., Kim J.S., Kim J.M., Lee J.Y., Jung H.C., Song I.S. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer 2008, 123:951-957.
13. Ahern T.P., Lash T.L., Damkier P., Christiansen P.M., Cronin-Fenton D.P. Statins and breast cancer prognosis: evidence and opportunities. Lancet Oncol 2014, 15:e461-e468.
14. Freed-Pastor W.A., Mizuno H., Zhao X., Langerod A., Moon S.H., Rodriguez-Barrueco R., et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012, 148:244-258.
15. Fang Z., Tang Y., Fang J., Zhou Z., Xing Z., Guo Z., et al. Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway. PLoS One 2013, 8:e62823.
16. Woodard J., Sassano A., Hay N., Platanias L.C. Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma. Clin Cancer Res 2008, 14:4640-4649.
17. Bil J., Zapala L., Nowis D., Jakobisiak M., Golab J. Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro. Cancer Lett 2010, 288:57-67.
18. Khurana V., Caldito G., Ankem M. Statins might reduce risk of renal cell carcinoma in humans: case-control study of 500,000 veterans. Urology 2008, 71:118-122.
19. Liu W., Choueiri T.K., Cho E. Statin use and the risk of renal cell carcinoma in 2 prospective US cohorts. Cancer 2012, 118:797-803.
20. Chiu H.F., Kuo C.C., Kuo H.W., Lee I.M., Lee C.T., Yang C.Y. Statin use and the risk of kidney cancer: a population-based case-control study. Expert Opin Drug Saf 2012, 11:543-549.
21. Hamilton R.J., Morilla D., Cabrera F., Leapman M., Chen L.Y., Bernstein M., et al. The association between statin medication and progression after surgery for localized renal cell carcinoma. J Urol 2014, 191:914-919.
22. Choi S.K., Min G.E., Jeon S.H., Lee H.L., Chang S.G., Yoo K.H. Effects of statins on the prognosis of local and locally advanced renal cell carcinoma following nephrectomy. Mol Clin Oncol 2013, 1:365-368.
23. Manoukian G.E., Tannir N.M., Jonasch E., Qiao W., Haygood T.M., Tu S.M. Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2011, 9:81-88.
24. Fine J.P., Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:494-509.
25. Brown M., Hart C., Tawadros T., Ramani V., Sangar V., Lau M., et al. The differential effects of statins on the metastatic behaviour of prostate cancer. Br J Cancer 2012, 106:1689-1696.
26. Coogan P.F., Rosenberg L., Strom B.L. Statin use and the risk of 10 cancers. Epidemiology 2007, 18:213-219.
27. Kuoppala J., Lamminpaa A., Pukkala E. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer 2008, 44:2122-2132.
28. Frank I., Blute M.L., Cheville J.C., Lohse C.M., Weaver A.L., Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002, 168:2395-2400.